ライフサイエンスコーパス: liraglutide

1 increased in mice treated with exendin-4 or liraglutide.

2 DegLira, 414 to insulin degludec, and 415 to liraglutide.

3 gludec, and by 1.3% (1.1) to 7.0% (1.2) with liraglutide.

4 control, with greater reductions noted with liraglutide.

5 control, with greater reductions noted with liraglutide.

6 -0.34% (-0.51 to -0.16, p<0.0001) for 1.2 mg liraglutide.

7 three groups: control, food-restricted, and liraglutide.

8 and improved metabolic parameters similar to liraglutide.

9 once weekly titrated to 50 mg at week 6, or liraglutide 0.6 mg once daily titrated to 1.2 mg at week

10 eceived subcutaneous injections of saline or liraglutide (0.005-0.015 mg/kg/day) for 30 days after am

11 Animals received liraglutide (0.2 mg/kg s.c.) or vehicle injections twice

12 ere treated for 8 days with the GLP-1 analog liraglutide (0.2 mg/kg twice daily), which restored NO b

13 CI -0.58 to -0.36, p<0.0001) and superior to liraglutide (-0.64%, -0.75 to -0.53, p<0.0001).

14 limepiride, compared with 0.84% (1.23%) with liraglutide 1.2 mg (difference -0.33%; 95% CI -0.53 to -

15 Five patients in the liraglutide 1.2 mg, and one in 1.8 mg groups discontinue

16 3 to -0.13, p=0.0014) and 1.14% (1.24%) with liraglutide 1.8 mg (-0.62; -0.83 to -0.42, p<0.0001).

17 and randomly assigned to receive additional liraglutide 1.8 mg once a day (n=233) or exenatide 10 mi

18 iabetes were randomly assigned to once daily liraglutide (1.2 mg [n=251] or 1.8 mg [n=247]) or glimep

19 centres to assess subcutaneous injections of liraglutide (1.8 mg daily) compared with placebo for pat

20 injections of IDegLira, insulin degludec, or liraglutide (1.8 mg per day).

21 subcutaneous liraglutide (3.0 mg) (n = 423), liraglutide (1.8 mg) (n = 211), or placebo (n = 212), al

22 s were reported with liraglutide (3.0 mg) vs liraglutide (1.8 mg) and placebo.

23 system, to receive injections of once-daily liraglutide (1.8 mg) or once-weekly exenatide (2 mg).

24 .3% with liraglutide (3.0 mg) and 40.4% with liraglutide (1.8 mg) vs 21.4% with placebo (estimated di

25 .2% with liraglutide (3.0 mg) and 15.9% with liraglutide (1.8 mg) vs 6.7% with placebo (estimated dif

26 ce-weekly dulaglutide (1.5 mg) or once-daily liraglutide (1.8 mg).

27 ith liraglutide (3.0-mg dose), 105.8 kg with liraglutide (1.8-mg dose), and 106.5 kg with placebo.

28 iraglutide (3.0-mg dose), 4.7% (5.0 kg) with liraglutide (1.8-mg dose), and 2.0% (2.2 kg) with placeb

29 0%, 95% CI -1.63 to -1.37, n=218) and 1.2 mg liraglutide (-1.24%, -1.37 to -1.11, n=221) than with si

30 (8.5% at baseline) was achieved with 1.8 mg liraglutide (-1.50%, 95% CI -1.63 to -1.37, n=218) and 1

31 placebo, -4.00% [95% CI, -5.10% to -2.90%]; liraglutide [1.8 mg] vs placebo, -2.71% [95% CI, -4.00%

32 placebo, 32.9% [95% CI, 24.6% to 41.2%]; for liraglutide [1.8 mg] vs placebo, 19.0% [95% CI, 9.1% to

33 8.5% [95% CI, 12.7% to 24.4%], P < .001; for liraglutide [1.8 mg] vs placebo, 9.3% [95% CI, 2.7% to 1

34 Supporting a direct mechanism of action, liraglutide (100 nmol/L) prevented palmitate-induced lip

35 tients given albiglutide than in those given liraglutide (12.9% vs 5.4%; treatment difference 7.5% [9

36 Liraglutide 3.0 mg might provide health benefits in term

37 web-based system, to once-daily subcutaneous liraglutide 3.0 mg or matched placebo, as an adjunct to

38 Liraglutide 3.0 mg was shown to reduce bodyweight and im

39 Once-daily, subcutaneous liraglutide (3.0 mg) (n = 423), liraglutide (1.8 mg) (n

40 loss greater than 10% occurred in 25.2% with liraglutide (3.0 mg) and 15.9% with liraglutide (1.8 mg)

41 loss of 5% or greater occurred in 54.3% with liraglutide (3.0 mg) and 40.4% with liraglutide (1.8 mg)

42 ts with type 2 diabetes, use of subcutaneous liraglutide (3.0 mg) daily, compared with placebo, resul

43 th no stratification to receive subcutaneous liraglutide (3.0 mg) or placebo, with standardised nutri

44 astrointestinal disorders were reported with liraglutide (3.0 mg) vs liraglutide (1.8 mg) and placebo

45 Baseline weight was 105.7 kg with liraglutide (3.0-mg dose), 105.8 kg with liraglutide (1.

46 Weight loss was 6.0% (6.4 kg) with liraglutide (3.0-mg dose), 4.7% (5.0 kg) with liraglutid

47 Both drugs promoted similar weight losses (liraglutide -3.24 kg vs exenatide -2.87 kg).

48 2 kg) with placebo (estimated difference for liraglutide [3.0 mg] vs placebo, -4.00% [95% CI, -5.10%

49 6.7% with placebo (estimated difference for liraglutide [3.0 mg] vs placebo, 18.5% [95% CI, 12.7% to

50 21.4% with placebo (estimated difference for liraglutide [3.0 mg] vs placebo, 32.9% [95% CI, 24.6% to

51 One-week treatment with liraglutide (30 microg/kg twice daily) did not reduce bo

52 kly dulaglutide (299 patients) or once-daily liraglutide (300 patients).

53 uded in the intention-to-treat analysis (450 liraglutide, 461 exenatide).

54 uded in the intention-to-treat analysis (450 liraglutide, 461 exenatide).

55 amate, 8.8 kg (95% CrI, -10.20 to -7.42 kg); liraglutide, 5.3 kg (95% CrI, -6.06 to -4.52 kg); naltre

56 Nausea was more common with liraglutide (59 [27%] patients on 1.8 mg; 46 [21%] on 1.

57 In a 52-week study with liraglutide, a dose-related increase in absolute pancrea

58 The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when ad

59 a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with pl

60 antidiabetic activities of NRTN relative to liraglutide, a glucagon-like peptide 1 receptor agonist,

61 Liraglutide, a glucagon-like peptide-1 analogue, has bee

62 We compared the efficacy and safety of liraglutide, a human GLP-1 analogue, with exenatide, an

63 The efficacy of liraglutide, a human glucagon-like peptide-1 (GLP-1) ana

64 Liraglutide, a long-acting GLP-1 receptor agonist, is ap

65 ific deletion of Glp1r and then administered liraglutide, a long-acting GLP1R agonist.

66 GLP-1 and liraglutide activate the GLP-1R, thereby promoting pre-a

67 lutide induces weight loss or to what degree liraglutide acts directly in the brain.

68 the glucagon-like peptide-1 receptor agonist liraglutide added to clozapine or olanzapine treatment o

69 stinal adverse events reported with degludec/liraglutide (adverse events, 79 for degludec/liraglutide

70 Adverse events with liraglutide affected mainly the gastrointestinal tract.

71 e investigate the neuroprotective effects of Liraglutide along with the signalling network against pr

72 Besides lowering blood glucose, liraglutide also reduces body weight.

73 LP-1 analogues showed efficacy comparable to liraglutide, an antidiabetic GLP-1 analogue that carries

74 24 (5%) patients allocated to liraglutide and 12 (3%) allocated to exenatide discontin

75 6 patients were randomly assigned to receive liraglutide and 26 to placebo.

76 Both once daily liraglutide and once weekly exenatide led to improvement

77 INTERPRETATION: Both once daily liraglutide and once weekly exenatide led to improvement

78 The liraglutide and placebo groups had comparable characteri

79 he glucagon-like peptide-1 receptor agonists liraglutide and semaglutide also reduced CV death and/or

80 Nine (39%) of 23 patients who received liraglutide and underwent end-of-treatment liver biopsy

81 r patient year was 1.8 for IDegLira, 0.2 for liraglutide, and 2.6 for insulin degludec.

82 the antihyperglycaemic drugs empagliflozin, liraglutide, and semaglutide-the latter being under revi

83 logues that can be given once daily, such as liraglutide, and the use of DPP-IV inhibitors in the man

84 besity; however, the mechanisms of action of liraglutide are incompletely understood.

85 Because GLP-1 and liraglutide are used for the treatment of type 2 diabete

86 These findings support the use of liraglutide as an effective GLP-1 agent to add to metfor

87 ed to investigate the safety and efficacy of liraglutide as monotherapy for this disorder.

88 d (FA) moiety that causes oligomerization of liraglutide as suggested by small-angle x-ray scattering

89 In this study, 3.0 mg of liraglutide, as an adjunct to diet and exercise, was ass

90 nd defective responses to the GLP-1 analogue liraglutide at 8 weeks.

91 eceive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or place

92 sary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r(-/-) mice.

93 Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) recept

94 Moreover, labeled liraglutide bound neurons within the arcuate nucleus (AR

95 mediate body weight and anorectic effects of liraglutide, but are not required for glucose-lowering e

96 Body weight decreased with liraglutide compared with placebo (-5.3 kg; 95% CI, -7.0

97 ; 95% CI, -23.2 to -7.7 mg/dL) occurred with liraglutide compared with placebo.

98 rgine and metformin, treatment with degludec/liraglutide compared with up-titration of glargine resul

99 exone-bupropion, phentermine-topiramate, and liraglutide, compared with placebo, were each associated

100 Compared with placebo, liraglutide delayed gastric emptying of solids at 5 week

101 Hearts from animals treated with liraglutide demonstrated decreased beta1-adrenoreceptor

102 LP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was

103 In conclusion, liraglutide did not induce pancreatitis in mice, rats, o

104 h heart failure and reduced LVEF, the use of liraglutide did not lead to greater posthospitalization

105 carried forward; seven patients assigned to liraglutide did not receive treatment and thus did not m

106 Here, we determined that liraglutide does not activate GLP-1-producing neurons in

107 wed an increase in the exocrine cell mass in liraglutide-dosed animals, with normal composition of en

108 using GLP-1R agonists addressing this issue (Liraglutide Effect and Action in Diabetes: Evaluation of

109 e GLP-1R agonists liraglutide (LEADER trial [Liraglutide Effect and Action in Diabetes: Evaluation of

110 Mechanistically, Liraglutide engages Akt and signal transducer and activa

111 Liraglutide enhanced the slope of the relationship betwe

112 fat-fed mice treated with the GLP-1R agonist liraglutide exhibited preservation of cardiac function.

113 d in monkeys dosed for 87 weeks, with plasma liraglutide exposure 60-fold higher than that observed i

114 y (margin 0.4%) of dulaglutide compared with liraglutide for change in HbA1c (least-squares mean chan

115 ly dulaglutide is non-inferior to once-daily liraglutide for least-squares mean reduction in HbA1c, w

116 ermined SAXS curves supporting the view that liraglutide forms heptamers in solution.

117 gut peptide GLP-1 or its long-lasting analog liraglutide, function as intestinally derived signals to

118 ge in HbA(1c) was greater in patients in the liraglutide group (-1.48%, SE 0.05; n=386) than in those

119 sea was the most common adverse event in the liraglutide group (12 of 19) compared with placebo (four

120 ients died from cardiovascular causes in the liraglutide group (219 patients [4.7%]) than in the plac

121 ate of death from any cause was lower in the liraglutide group (381 patients [8.2%]) than in the plac

122 urred in significantly fewer patients in the liraglutide group (608 of 4668 patients [13.0%]) than in

123 lerated volume at 16 weeks, was lower in the liraglutide group (median 750 mL [IQR 651 to 908]) compa

124 disorders in 21 (81%) of 23 patients in the liraglutide group and 17 (65%) of 22 patients in the pla

125 withdrawal of 714 (47%) participants in the liraglutide group and 412 (55%) participants in the plac

126 seline HbA1c level was 8.4% for the degludec/liraglutide group and 8.2% for the glargine group.

127 ents occurred in 6.2% of the patients in the liraglutide group and in 5.0% of the patients in the pla

128 of renal adverse events were similar in the liraglutide group and the placebo group (15.1 events and

129 A total of 63.2% of the patients in the liraglutide group as compared with 27.1% in the placebo

130 Glucose tolerance improved in the liraglutide group compared with the placebo group (P < .

131 required eight (38%) of 21 successes in the liraglutide group for the effect of liraglutide to be co

132 At week 56, patients in the liraglutide group had lost a mean of 8.4+/-7.3 kg of bod

133 ents in the abliglutide group and 408 in the liraglutide group received the study drugs.

134 rticipants in the IDegLira group than in the liraglutide group reported gastrointestinal adverse even

135 which occurred in fewer participants in the liraglutide group than in the placebo group (161 vs. 215

136 utcome occurred in fewer participants in the liraglutide group than in the placebo group (268 of 4668

137 lso significantly greater weight loss in the liraglutide group than in the placebo group (at 5 weeks:

138 ncreatitis was nonsignificantly lower in the liraglutide group than in the placebo group.

139 t failure were nonsignificantly lower in the liraglutide group than in the placebo group.

140 , which occurred in 49.0% of patients in the liraglutide group versus 35.9% in the albiglutide group

141 week 160, 26 (2%) of 1472 individuals in the liraglutide group versus 46 (6%) of 738 in the placebo g

142 (SD 47) weeks for the 26 individuals in the liraglutide group versus 87 (47) weeks for the 46 indivi

143 f 1501 randomised treated individuals in the liraglutide group versus 96 (13%) of 747 individuals in

144 Two (9%) of 23 patients in the liraglutide group versus eight (36%) of 22 patients in t

145 glutide vs glargine (-1.81% for the degludec/liraglutide group vs -1.13% for the glargine group; esti

146 primary end point (mean rank of 146 for the liraglutide group vs 156 for the placebo group, P = .31)

147 ces in the number of deaths (19 [12%] in the liraglutide group vs 16 [11%] in the placebo group; haza

148 ted hyperglycemic events was 16 (10%) in the liraglutide group vs 27 (18%) in the placebo group and h

149 adverse events were nausea (93 [21%] in the liraglutide group vs 43 [9%] in the exenatide group), di

150 ncluded diarrhoea (ten [38%] patients in the liraglutide group vs five [19%] in the placebo group), c

151 61 [20%] in dulaglutide group vs 54 [18%] in liraglutide group), diarrhoea (36 [12%] vs 36 [12%]), dy

152 e dulaglutide group and -1.36% (0.05) in the liraglutide group.

153 in degludec group, and 14 (3%) of 412 in the liraglutide group.

154 ants in the albiglutide group and 403 in the liraglutide group.

155 astrointestinal events than did those in the liraglutide group.

156 e enrolled and randomly allocated (19 to the liraglutide group; 21 to the placebo group).

157 ated to the albigultide group and 419 to the liraglutide group; 404 patients in the abliglutide group

158 ite group and -0.99% (-1.08 to -0.90) in the liraglutide group; treatment difference was 0.21% (0.08-

159 e in the control group and 3 mice in all the liraglutide groups (of 66-76 mice per group).

160 oup and 2, 1, 1, and 1 mice in the different liraglutide groups (of 67-79 mice per group) had pancrea

161 Patients who received once-daily liraglutide had greater reductions in HbA1c than did tho

162 Compared with placebo, liraglutide had no significant effect on the primary end

163 Compared to GLP-1, liraglutide has an added fatty acid (FA) moiety that cau

164 the glucagon-like peptide-1 (GLP-1) analogue liraglutide has been developed as a once-daily injection

165 ke peptide-1 receptor agonists exenatide and liraglutide have been shown to improve glycaemic control

166 e aimed to compare combined insulin degludec-liraglutide (IDegLira) with its components given alone i

167 Liraglutide improved the cardiac endoplasmic reticulum s

168 either the synthetic GLP-1 receptor agonist liraglutide in a dose-escalating regimen to reverse hype

169 ffects of the glucagon-like peptide-1 analog liraglutide in a model of obesity, independent of change

170 on, and, recently, a pilot clinical trial of Liraglutide in Alzheimer's disease patients showed impro

171 e-weekly dulaglutide with that of once-daily liraglutide in metformin-treated patients with uncontrol

172 eripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in

173 dy weight caused by the central injection of liraglutide in other hypothalamic sites was sufficiently

174 These findings do not support the use of liraglutide in this clinical situation.

175 jection of a clinically used GLP-1R agonist, liraglutide, in mice stimulates brown adipose tissue (BA

176 efficacy of the long-acting GLP-1 analogue, liraglutide, in patients with non-alcoholic steatohepati

177 ists, once-weekly albiglutide and once-daily liraglutide, in patients with type 2 diabetes inadequate

178 nion are orlistat, naltrexone/bupropion, and liraglutide; in the USA, lorcaserin and phentermine/topi

179 Liraglutide increased diastolic relaxation (dP/dt; Tau (

180 ear with GLP-1R agonists, both exenatide and liraglutide increased energy expenditure.

181 ntain the same body weights, suggesting that liraglutide increases energy expenditure.

182 Liraglutide induced greater weight loss than placebo at

183 his area is sufficient to blunt both central liraglutide-induced thermogenesis and adipocyte browning

184 /CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.

185 It is not fully understood how liraglutide induces weight loss or to what degree liragl

186 Liraglutide is a glucagon-like peptide-1 (GLP-1) analog

187 Liraglutide is an acylated glucagon-like peptide-1 (GLP-

188 Liraglutide is safe and effective as initial pharmacolog

189 The glucagon-like peptide 1 (GLP-1) analog, liraglutide, is a GLP-1 agonist and is used in the treat

190 rdiovascular event) with the GLP-1R agonists liraglutide (LEADER trial [Liraglutide Effect and Action

191 diabetic retinopathy (DR) were neutral with liraglutide (LEADER) or worse when compared with placebo

192 of native GLP-1 and several GLP-1R agonists (liraglutide, lixisenatide, and exenatide).

193 The results suggest that liraglutide might be a treatment option for type 2 diabe

194 We show that Liraglutide modulates the ER stress response and elicits

195 The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily s

196 1:1 randomization to degludec/liraglutide (n = 278; maximum dose, 50 U of degludec/1.8

197 e randomly assigned 2254 patients to receive liraglutide (n=1505) or placebo (n=749).

198 given 6 months GLP-1 RA (exenatide, n = 19; liraglutide, n = 6).

199 Liraglutide, naltrexone/bupropion, and phentermine/topir

200 Interestingly, coadministration of NRTN and liraglutide normalized hyperglycemia and other metabolic

201 However, the long-term effects of liraglutide on renal outcomes in patients with type 2 di

202 INTERPRETATION: Effects of liraglutide on weight loss are associated with delay in

203 Liraglutide once a day provided significantly greater im

204 acy and safety of exenatide once weekly with liraglutide once daily in patients with type 2 diabetes.

205 .2 mg (n=225) or 1.8 mg (n=221) subcutaneous liraglutide once daily, or 100 mg oral sitagliptin once

206 Liraglutide or placebo was escalated by 0.6 mg/day each

207 ks with once-daily subcutaneous injection of liraglutide or placebo.

208 l in which patients were assigned to receive liraglutide or placebo.

209 ia spectrum disorder, 103 were randomized to liraglutide or placebo.

210 etes and high cardiovascular risk to receive liraglutide or placebo.

211 ical changes in the pancreas associated with liraglutide or semaglutide, two structurally different G

212 gon-like peptide 1 receptor (GLP-1R) agonist liraglutide or the highly selective DPP4 inhibitor MK-06

213 Compared with placebo, liraglutide (OR, 2.95; 95% CrI, 2.11-4.23) and naltrexon

214 85; SUCRA, 0.95), 63% of participants taking liraglutide (OR, 5.54; 95% CrI, 4.16-7.78; SUCRA, 0.83),

215 78; maximum dose, 50 U of degludec/1.8 mg of liraglutide) or glargine (n = 279; no maximum dose), wit

216 ntractility) increased with dobutamine after liraglutide (P < 0.001) but not saline administration (P

217 imepiride, insulin glargine, insulin lispro, liraglutide, pioglitazone, or sitagliptin).

218 mmol/L) in the presence of GLP-1 (100 nmol/L liraglutide) presented a greater SIRT6 and lower nuclear

219 systemic administration of a GLP-1R agonist (liraglutide) prevents retinal neurodegeneration (glial a

220 Liraglutide reduced mean fasting plasma glucose more tha

221 Liraglutide reduced mean HbA(1c) significantly more than

222 alysis shows that, when added to usual care, liraglutide resulted in lower rates of the development a

223 who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end p

224 d ZDF rats with sustained hyperglycemia with liraglutide resulted in some alleviation of hyperglycemi

225 d with change in weight loss at week 16 with liraglutide (Rs 0.567, p=0.018).

226 ll cardiovascular efficacy for lixisenatide, liraglutide, semaglutide, and extended-release exenatide

227 Liraglutide significantly improved glucose tolerance, bo

228 re identified: ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN 6 (semaglutide), and EXSCEL (exten

229 ) and minor hypoglycaemia less frequent with liraglutide than with exenatide (1.93 vs 2.60 events per

230 omised individuals was 2.7 times longer with liraglutide than with placebo (95% CI 1.9 to 3.9, p<0.00

231 with type 2 diabetes mellitus was lower with liraglutide than with placebo.

232 We investigated whether liraglutide, the once-daily human GLP-1 analog, induces

233 s in the liraglutide group for the effect of liraglutide to be considered clinically significant.

234 are also required for peripherally injected liraglutide to reduce feeding and weight.

235 In contrast, liraglutide-treated animals exhibited lower fasting plas

236 Furthermore, energy-restricted and liraglutide-treated animals exhibited more normal islet

237 estricted animals had lower food intake than liraglutide-treated animals to maintain the same body we

238 Altogether, 30 liraglutide-treated participants (63.8%) developed norma

239 However, unlike liraglutide-treated rats, NRTN-mediated improvements wer

240 food restricted to equalize body weights to liraglutide-treated rats.

241 control animals compared with restricted and liraglutide-treated rats.

242 Liraglutide treatment delayed diabetes onset by 4.1 +/-

243 Liraglutide treatment delays the development of diabetes

244 p to 6 months of age, energy restriction and liraglutide treatment lowered fasting plasma glucose and

245 s were elevated in STZ-DM rats, and although liraglutide treatment lowered glucagon levels to those o

246 Liraglutide treatment provided beneficial glucose-loweri

247 Chronic liraglutide treatment reduced body weight in chow-fed GL

248 ss and proliferation rates were unaltered by liraglutide treatment.

249 GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding

250 We compared effects of liraglutide versus placebo on gastric motor functions, s

251 The efficacy of liraglutide versus sitagliptin was assessed hierarchical

252 Estimated mean treatment differences for liraglutide versus sitagliptin were -0.60% (95% CI -0.77

253 icacy and safety of the human GLP-1 analogue liraglutide versus the DPP-4 inhibitor sitagliptin, as a

254 ght gain with glargine (-1.4 kg for degludec/liraglutide vs 1.8 kg for glargine; ETD, -3.20 kg [95% C

255 liraglutide (adverse events, 79 for degludec/liraglutide vs 18 for glargine).

256 des/patient-year exposure, 2.23 for degludec/liraglutide vs 5.05 for glargine; estimated rate ratio,

257 1c level reduction was greater with degludec/liraglutide vs glargine (-1.81% for the degludec/liraglu

258 If noninferiority of degludec/liraglutide was achieved, secondary end points were test

259 Treatment with degludec/liraglutide was also associated with weight loss compare

260 gon-like peptide-1 receptor (GLP-1R) agonist liraglutide was designed, synthesized, and tested.

261 LP1R in the CNS or visceral nerves; however, liraglutide was ineffective at altering food intake, bod

262 In the ARC, liraglutide was internalized in neurons expressing proop

263 Liraglutide was safe, well tolerated, and led to histolo

264 Liraglutide was superior to sitagliptin for reduction of

265 Phentermine-topiramate and liraglutide were associated with the highest odds of ach

266 rse events leading to the discontinuation of liraglutide were gastrointestinal events.

267 most frequently reported adverse events with liraglutide were mild or moderate nausea and diarrhea.

268 of peripherally dosed GLP-1RA exendin-4 and liraglutide were preserved in all mouse lines.

269 .06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased.

270 portant to know the oligomerization state of liraglutide with respect to stability.

271 of 0.3%), and the superiority of IDegLira to liraglutide (with a lower 95% CI margin of 0%).

272 rom baseline in HbA1c for albiglutide versus liraglutide, with a 95% CI non-inferiority upper margin

273 The primary hypothesis was that liraglutide would be noninferior to placebo with regard